Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
CytomX (CTMX) Stock Surges on Oncology Deal With Regeneron
06:18pm, Friday, 18'th Nov 2022 Zacks Investment Research
CytomX (CTMX) gets a boost after its deal with Regeneron for the development of investigational next-generation bispecific immunotherapies.
Regeneron Pharmaceuticals, Inc. (REGN) Jefferies London Healthcare Conference - (Transcript)
12:24pm, Wednesday, 16'th Nov 2022
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Jefferies London Healthcare Conference November 16, 2022 10:15 AM ET Company Participants Ryan Crowe - VP, IR Robert Landry - EVP, Finance & CFO Conferen
Bayer (BAYRY) Eylea Label Extension Gets CHMP Positive Opinion
03:10pm, Monday, 14'th Nov 2022 Zacks Investment Research
Bayer (BAYRY) gets positive recommendation from the CHMP for label extension of ophthalmology drug Eylea for the treatment of preterm infants with retinopathy of prematurity.
Sanofi (SNY), Regeneron Dupixent Gets CHMP Nod for Skin Disease
12:43pm, Monday, 14'th Nov 2022 Zacks Investment Research
The CHMP recommends approval of Sanofi's (SNY) Dupixent for the treatment of prurigo nodularis, a chronic inflammatory skin disease.
2 Top Biotech Stocks to Buy in November
03:15pm, Saturday, 12'th Nov 2022 The Motley Fool
Both of these companies have potential catalysts on the way.
2 Top Biotech Stocks to Buy in November
10:15am, Saturday, 12'th Nov 2022
Both of these companies have potential catalysts on the way.
Kodiak Sciences' (KOD) Q3 Earnings Beat, Eye Candidate in Focus
07:17pm, Thursday, 10'th Nov 2022 Zacks Investment Research
Kodiak Sciences (KOD) reports a narrower-than-expected loss for the third quarter of 2022. The focus is on the lead candidate, KSI-301, developed for treating various retinal vascular diseases.
Biotech Stock Roundup: REGN, AMGN, MRNA's Q3 Earnings, VERV Down on Update
05:35pm, Wednesday, 09'th Nov 2022 Zacks Investment Research
Earnings updates from REGN and MRNA are the key highlights from the biotech sector during the past week.
Regeneron (REGN) Gets FDA Nod for Libtayo's Label Expansion
03:43pm, Wednesday, 09'th Nov 2022 Zacks Investment Research
Regeneron (REGN) obtains FDA approval for the second advanced NSCLC indication, which expands the patient population eligible for a Libtayo-based regimen to include combination treatment with chemothe
Regeneron (REGN) Gets FDA Nod for Libtayo's Label Expansion
12:02pm, Wednesday, 09'th Nov 2022
Regeneron (REGN) obtains FDA approval for the second advanced NSCLC indication, which expands the patient population eligible for a Libtayo-based regimen to include combination treatment with chemothe
Bayer's (BAYRY) Q3 Earnings Miss Estimates, Revenues Top
03:40pm, Tuesday, 08'th Nov 2022 Zacks Investment Research
Bayer's (BAYRY) earnings fall shy of estimates in the third quarter of 2022 while revenues beat the same.
7 Cash-Rich Stocks to Buy for Peace of Mind
02:22pm, Friday, 04'th Nov 2022
Companies of all sizes appear to be hoarding cash for the much-discussed impending recession. If we do dive into a recession, cash-rich stocks will be more than prepared for whatever slowdown comes th
Regeneron (REGN) Q3 Earnings & Sales Beat on Eylea, Dupixent
12:47pm, Thursday, 03'rd Nov 2022
Regeneron (REGN) tops earnings and sales estimates for the third quarter, driven by its lead drug Eylea and profits from the asthma drug, Dupixent. However, earnings decline year over year.
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2022 Earnings Call Transcript
12:07pm, Thursday, 03'rd Nov 2022
Regeneron Pharmaceuticals, Inc. (AAPL) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Ryan Crowe - Vice President, Investor Relations Leonard Schleifer - President,
Regeneron (REGN) Surpasses Q3 Earnings and Revenue Estimates
09:50am, Thursday, 03'rd Nov 2022
Regeneron (REGN) delivered earnings and revenue surprises of 14.85% and 5.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
